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Editor Speech of IC - BTI 2020
International Conference is the 9th international interdisciplinary peer reviewed conference which publishes
works of the scientists as well as practitioners in the area where UBT is active in Education, Research and
Development. The UBT aims to implement an integrated strategy to establish itself as an internationally
competitive, research-intensive institution, committed to the transfer of knowledge and the provision of a
world-class education to the most talented students from all backgrounds. It is delivering different courses in
science, management and technology. This year we celebrate the 19th Years Anniversary. The main
perspective of the conference is to connect scientists and practitioners from different disciplines in the same
place and make them be aware of the recent advancements in different research fields, and provide them with
a unique forum to share their experiences. It is also the place to support the new academic staff for doing
research and publish their work in international standard level. This conference consists of sub conferences
in different fields: - Management, Business and Economics - Humanities and Social Sciences (Law, Political
Sciences, Media and Communications) - Computer Science and Information Systems - Mechatronics,
Robotics, Energy and Systems Engineering - Architecture, Integrated Design, Spatial Planning, Civil
Engineering and Infrastructure - Life Sciences and Technologies (Medicine, Nursing, Pharmaceutical
Sciences, Physcology, Dentistry, and Food Science),- Art Disciplines (Integrated Design, Music, Fashion,
and Art).
This conference is the major scientific event of the UBT. It is organizing annually and always in cooperation
with the partner universities from the region and Europe. In this case as partner universities are: University
of Tirana – Faculty of Economics, University of Korca. As professional partners in this conference are:
Kosova Association for Control, Automation and Systems Engineering (KA – CASE), Kosova Association
for Modeling and Simulation (KA – SIM), Quality Kosova, Kosova Association for Management. This
conference is sponsored by EUROSIM - The European Association of Simulation. We have to thank all
Authors, partners, sponsors and also the conference organizing team making this event a real international
scientific event. This year we have more application, participants and publication than last year.
Congratulations!
Edmond Hajrizi,
Rector of UBT and Chair of IC - BTI 2020
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Determination of aerobic mesophilic bacteria as well as coliforms in a
raw milk in the region of Prizren, Suhareka and Rahovec
4

Hyzer Rizani1, Shkelzim Ukaj1, Shkumbin Shala1, Magbule Rizani1, Naser Kamberi1, Smajl Rizani1,
Duresa Ukaj1
1Faculty

of Food and Technology Sciences, UBT- Higher Education Institution, Lagjja Kalabria p.n., 10000 Prishtina,
Republic of Kosovo
Corresponding author; E-mail: shkelzim.ukaj@ubt-uni.net

Abstract:The microbiological quality of raw milk is a key to the quality production of dairy products.
Alternation is a term that describes the change of composition, taste and smell at those points where it is
inedible for the consumer. Microbial alternation of milk often involves degradation of proteins, carbohydrates
and fats of organisms and their enzymes. Milk and dairy consumption has increased considerably in Kosovo
over the last decade, and a large part of local production comes from small-scale distributors across the
country. In this research, 50 milk samples were taken at some of the cumulative sites and from dairy farms
in three Kosovo municipalities (Prizren, Suhareka and Rahovec). The microbiological quality of the milk
samples is analyzed according to official standards. Further, in raw milk, a number of aerobic mesophilic
bacteria and a number of coliforms were analyzed. Aerobic mesophilic bacteria in fresh milk, used as raw
material, did not show more than 2.0×10 6 cfu/ml, whereas coliforms were presented at 4cfu / ml.
Keywords: milk, mesophilic, aerobic, coliform, cfu.

Introduction
Milk is an ideal environment, with a high water content, rich nutritional elements and with an almost neutral
pH (pH 6,4 – 6,8) that favors the growth of many microorganisms. Microorganisms in milk can be classified
in two main groups: pathogens and responsible microorganisms of the demolition where some of them can
play a multiple role (ex. Bacillus cereus) [2]. Pathogens microorganisms represent a threat to public health.
Due to their enzymes (ex. proteases, peptidase, lipase, esterase, oxidase, polymerase, β-galaktozidaza),
responsible microorganisms of demolition are able to hydrolyzate the milk ingridients, such as protein, fat
and lactose appropriately, to gain neccesaryingridients for their growth [1].
Such reactions can cause demolition of milk ,accompained by a change of smell and taste, changes in the
quality and view of milk [6]. Microorganisms in milk are mainly spread in dirty environments of farm (ex.
faeces, straw chessis and soil. Microorganisms of outer part of the suction can be inserted into the canal of
the udder and may cause mastitis (Makovec & Ruegg, 2003) [9]. In conclusion, we can say that sources of
contamination are the inadequacy of milking equipment purity, which then pass in milk [3].

Material and Methods
50 samples were taken in some selling points in Prishtina, Rahovec and Lipjan. Immediately,after the samples
were taken, from the delivery place, samples must be put in the freezer compartment, then we make sure to
mix the samples to complete homogeneity. Afterward,an amount of 30ml of milk is transferred in a sample
container. For every sample we have used a test tube. The samples are transferred in 0-4 C temperature, until
they were brought to the laboratory.
Examination methods of aerobic mesophilebacteria is based in ISO- 4832-1:2013 [7]. Microbiology of food
chain- Horizontal methods of microorganisms counting. First part: counting in 30C through pouring
technique and the method of Coliforms ISO 4832:2006. The microbiology of food and animal food productsHorizontal method of coliforms counting - Counting technique [8].
For counting of aerob mesophiles are taken two Petrit’s plates. The transfer is made for each by steril pipette
from 1 ml of sample. Only critical dilutions are taken for inoculin in the Pjetrit’s plate, to develop a colony
between 150-300 per plate. For the nutritional area used plate count is approximately 12-15 mL in a
temperature of 44-470C in each plate. The duration from the preparation time of the initial dilution to the
pouring of the feeding terrain in plates does not last more than 45 minutes.
The plates were carefully mixed and are left to stand in rigid horizontal positions until they are hardened. the
plates are incubated in a temperature of 300 ᵒC ±10C for 72h ±3h.
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The counting of colonies were made as follows, plates with more than 15 colonies and less than 300
colonies were counted.

Figure 1: Coliforms in the Violet Bile LactosAgar

Figure 2: Mesophilic aerobic bacteria on Plate Count Agar

After the incubation, using the calculator is made a counting for specific colonies. For the counting of
coliforms is used a hardened nutritional terrain, Crystal violet neutral red bile lactose (VRBL) agar. The
microbiology of food and animal food- - Preparation of samples, initial dilution and decimal dilution for
microbiological examination. Drying or Moisture Sterilization Equipment (Autoclaves), Incubator, Petri's
Plates, 90 mm, Pipettor, 1 ml, Water Baths, counter of colonies, tube tests, Durham Tubes, lab bottles, pHmeter, Eza from platinum – iridium or nicel-crome, approxiamately 3mm per diameter, or eza for one use.
Two plates are taken, where the tested material was transferred by 1ml sterile pipette from the corresponding
dilution, in the center of each plate. Then, 15ml of VRBLA are thrown in a temperature of 44 °C - 47 °C in
each Petri plate. After the complete hardening, 4 ml of the VRBLA terrain were thrown in 44°C to 47°C, on
the surface of inoculated terrains. After the hardening, the plates were incubated in 37°C per 24 h± 2 h.
After the appointed period of incubation, Petri’s plates with more than 10 colonies and less than 150 colonies
were taken for counting. The counting was made using the counting equipment of colonies, the colonist in
red with a diameter at least 0/5 mm (sometimes surrounded by the red precipitated zones. The confirmation
was made by pointing 5 typical colonies, in a liquid area Briliant green lactose, incubated in 37°C
temperature.per 24 h± 2 h. There were counted only the colonies that formed gas in Durham tubes. The
formula for the counting of the bacterial colonies is as follows:
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ΣC
N = ------------------------- x d
V x (n1 x 0.1 + n2)
* N – the number of microorganisms in 1 g sample
*ΣC – the amount of microorganisms in counted plates
*n1 – the number of plates in the initial dilution
* n2 – the number of plates in the second dilution
*d – the dilution factor.

Results and Discussion
In the table below, are given data for every type of fresh milk, for each sample through a research
process. The data are the average values of analyzed samples during this study for mesophile bacterias
and coliforms in fresh milk. Generally, inside the analyzed type of milk could have been big deviations
of measured values.

Table 1. The general number of mesophilic bacterias and coliforms in fresh milk in the regions of
Prishtina, Rahovec and Lipjan.
Regions
Prizren
Rahovec
Suhareka
Average

The average of mesophile aerob bacteria
1.90x106 cfu/mL
2.60x106 cfu/mL
2.10x106 cfu/mL
2.20x106 cfu/mL

The average number of coliforms
3.35 cfu/mL
4.06 cfu/mL
4.59 cfu/mL
4.00 cfu/mL

From the taken results we can see the total mesophilic bacterial microflora is under the standard norms in
three regions: Prizren1.90x106 cfu/mL, Rahovec 2.60x106 cfu/mL, Suhareka 2.10x106 cfu/mL, and the total
average is 2.20x106 cfu/mL. The content of coliform microorganisms is within the limit prescribed by the
standard. The high presence of coliform is found in Suhareka region 4.59 cfu/mL, then in Rahovec 4.06
cfu/mL and Prizren 3.35 cfu/mL.
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The concentration of microorganisms depends on the type of microorganisms, the state of infection within
the infection, the infestation phase and the infected fecal fraction that constitutes a normal state of milk
production and the detection of pathogens mainly transmitted by cows to cows, with or without intermediate
mediator. Pollution is mainly transmitted to milk when it is in contact with the outside of the suction and its
content decreases during the filtration system at milking time [3]. The content of coliform microorganisms
is in the described limit from the standard. The highest presence of coliforms is found in the region of
Suhareka 4.59 cfu/ml, then in Rahovec 4.06 cfu/ml and in Prizren 3.35 cfu/ml. Milk contains a variety of
microorganisms, however microbial content increases from bedding during fecal contamination. Moreover,
the high number of coliforms (7-9log10 cfu g-1) was measured also in used lofts. [10]. In the second year
prevails a high load of thermophilic bacteria comparing to the content of the bacteria mesophile

Conclusions
Bacterial microflora is studied to evaluate the hygiene of the production system, before the usage, which then
is reflected in the bacterial loads of milk after pasteurization. Every fresh milk contains a total bacterial
microflora inside the standard.
During the determination of the number of aerobic mezophilic bacteria in the region of Prizren we have
Starting from the content of coliforms that have resulted in each fresh milk, results in a re-contamination
after usage, telling of poor hygiene practices. For this reason, it is recommended maintaining aspectual
conditions in the tubes of processing and packaging lines.
In conclusion, we can say that sources of contamination are the inadequacy of the purity of the milking
equipment, which then passes on milk.
It is recommended to store the unprocessed milk in 2 0C, which has resulted to be effective in the growth of
fresh milk life compared to the store beyond 4 0C and 70C.
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Abstract.The newly identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that
originated in December 2019 in Wuhan, China. By July 2020, the WHO reported over 17 million
confirmed cases in over 200 countries around the globe. This review discusses how the COVID-19
pandemic may affect healthy people, structure and replication cycle of SARS-CoV-2; targets and
therapeutics SARS- CoV-2 and anti-COVID drugs: strategies and perspectives.
Keywords: SARS-CoV-2, structure and replication, therapeutics drugs, multidrug combination,
transmission of SARS-CoV-2
1.

Introduction

The SARS-CoV-2 pandemic, declared as a global health emergency by the WHO in February 2020, has
currently infected more than 17 million people with fatalities near 700,000 and increasing exponentially, in
absence of vaccines and drugs. In this review, we focus on potential drug gable targets and suitable
therapeutics, currently being explored in clinical trials, to treat SARS-CoV-2 infection.
The coronavirus disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) that has posed serious threats to humans. The SARSCoV-2 infection emerged in December 2019. Soon, it spread across the globe causing a pandemic and has
become a major health concern [1, 2]. As of 1st June 2020, the WHO reported a total of 17,057,853 cases
world wide with 690,166 deaths due to COVID-19 [3].
Coronaviruses belong to the Coronoviridae family, consisting of four genera, namely Alphacoronavirus,
Betacoronavirus, Gammacoronavirus and Deltacoronavirus.
The SARS-CoV-2 belongs to the Betacoronavirus genera [4]. Like all coronaviruses, SARS-CoV-2 is a
positive stranded, non-segmented RNA virus. It is shown that coronaviruses have the largest genome
among all of RNA viruses, ranging from 27–32 kD [5]. Clinical features of SARS-CoV-2 infection are
similar to SARS and MERS. Clinical symptoms of SARSCoV-2 infection include fever, fatigue, dry cough
and dyspnea, which may progress into acute respiratory distress syndrome (ARDS) causing death [5].
SARS-CoV-2 is highly contagious and has exhibited transmission through fomites, cough and cold droplets
and human contact [2].
1.1 Structure & replication cycle of SARS-CoV-2
The SARS-CoV-2 has a spherical and pleomorphic form [7]. SARS-CoV-2 has a single-stranded,
nonsegmented, positive sense RNA. Most of the genomic material is constituted by the replicase gene,
which codes for 16 nonstructural proteins (nSPs). The rest of the genome codes for structural proteins (SPs)
of the virus [2, 16].
The structural proteins of SARS-CoV-2 are: a) spike glycoprotein (S), b) nucleocapsid proteins (N), c)
membrane proteins (M) and d) envelope proteins (E) [6, 8, 9, 16]. The spikes are seen as protrusions from
the virus surface, giving the appearance of a crown to the virus (fig.1).
The S proteins are glycoproteins, which help SARS-CoV-2 to attach and penetrate the virus into the host
cell [6].
The S protein is made by 2 subunits – which are called S1 and S2. The main function of S1 is to bind for
the host cell receptor; S2 is involved in fusion of the viral and cell membranes [11]. The S protein has to be
primed for activation and entry of the SARS-CoV-2 into the host cell [12, 13, 14, 15].
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The RNA genome of SARS-CoV-2 is packaged inside of capsid, the capsid is formed by the N proteins,
surrounded by a phospholipid bilayer envelope [6, 16]. The M and E proteins are embedded in the viral
envelope and are involved in post RNA translation of SARS-CoV-2. The function of M proteins is to
interact with other structural proteins, and in this form aid formation of envelope and bud release [2, 6, 16].
E proteins play a pivotal role in ion channels and are also involved in the assembly of the virus during
replication [16].
1.2 Replication cycle of SARS-CoV-2
The replication cycle of SARS-CoV-2 is divided into three processes – first is viral entry, second RNA
replication, assembly and third exit from the host cell.
It is supposed that some host cell proteins will be associated with the S protein of SARS-CoV-2, and in
this way facilitate viral invasion into cells. It was reported that SARS-CoV-2 uses angiotensin-converting
enzyme 2 (ACE2) as a receptor for entry into the host cell, similar to SARS-CoV [11, 13, 15, 17].
Also recent studies from different research groups show two other receptors which are involved; GRP78
and CD147. CD147, is placed on the surface of a transmembrane glycoprotein of the host cell and has been
proposed as an alternative pathway for infection [18, 19, 20]. Publication from this authors predicted the
binding of S protein to GRP78; a chaperone heat shock protein in cells.
It is shown that receptor binding domain (RBD) of S1 subunit binds to ACE2 on the cell surface. To
inactivate S protein it is necessary to cleaved at the S1/S2 and S2’ sites for further viral entry into the host
cell. Other studies on the coronavirus S proteins have reported many host proteases which are involved in
the spike activation like TMPRSS2, cathepsin L, B, furin and trypsin; this is shown by many authors [9, 14,
15]. Depending on their availability, the mechanism of viral entry differs; previous reports have recorded
entry of SARS-CoV either via an endocytic pathway or direct fusion with plasma membrane.
Many authors report that surface proteases of the host cells like TMPRSS2 (exogenous trypsin) can
cleave the S protein, and in this way triggering fusion of viral and plasma membranes, facilitating direct
release of the viral genome into the cytoplasm. The same authors report that SARS-CoV can also enter the
cell by endocytosis. Endosomal cathepsin B and L cleave the S protein, and in this form resulting in fusion
of the viral and endosomal membranes and subsequent release of viral genome [9, 13, 14, 15, 21, 22].
Once the virus enters the host cell, it releases the RNA genome into the cytoplasm. The gene called
replicase on the positive sense of RNA is directly translated to a polyprotein, pp1ab. After that the
polyprotein pp1ab after that is cleaved by viral proteases; 3-chymotrypsin like protease (3-CL pro) and
papain like protease (PL-pro) to form 16 individual nSPs [23]. In another side nSPs, on assembly, form the
RNA replicase-transcriptase complex (RTC). The RTC is localized in the double membrane vesicle (DMV)
near the ER [9]. It is shown that RTC is involved in replicating and transcribing the RNA genome into a set
of negative sense RNAs. Full-length of negative sense of RNAs act as templates for transcribing the
genomic RNA. Discontinuously replication by RTC forms partial, negative sense, subgenomic RNA
strands. These act as templates for transcription of subgenomic mRNA which code structural proteins (SPs)
of the virus [2, 9, 16, 24, 25, 26]. After that mRNA is translated using the cellular ribosomes and in this
form are produced the M, N, E, S proteins. Than the SPs are inserted into the ER, from where they are
transported to the ER-Golgi Intermediate Complex (ERGIC). In another way the N protein enclosing the
genomic RNA with other SPs in ERGIC, and forming viral buds. In the end the mature virions are
transported to the cell membrane in a vesicle and in this form they exit the host by exocytosis [2, 16, 9, 24,
25].
1.3 Targets & therapeutics SARS-CoV-2
As we said before the SARS-CoV-2 contains a single-stranded, RNA genome, the largest RNA virus
identified till today, which is very similar to the virus that causes SARS and MERS. COVID-19 belongs to
the β-coronavirus genus and after sequencing it is shown that 88% sequence homology with bat-SLCoVZC45 and bat-SL-CoVZC21, and 50% sequence has homology with MERSCoV [27, 28].
This sequencing give us possibilities to show construction of genome of SARS COVID-2. The genome
of SARS-CoV-2 is constructed at least by ten open reading frames (ORFs). The first ORF (ORF1ab),
encodes 1–16 NSP at the consensus cleavage site. Other ORFs, encode four major structural proteins, such
as spike (S), envelope (E), nucleocapsid (N), membrane (M) proteins and several other proteins with
unknown functions. As it discussed before the SARS-CoV-2 replication cycle mainly includes virus entry,
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genome replication, assembly and germination of virions. Interruption of any of this stages of replication
are a potential strategy for the development of antiviral agents (Figure 2).
1.4 Anti-COVID drugs: strategies and perspectives
Till today there are currently no effective drugs targeting SARS-CoV-2. Topical methods used to control
novel viral diseases is repurposing existing drugs or designing totally new entitled.
Apart from antiviral drugs, in the search area are also drugs from other groups, for example
cardiovascular, antibacterial, antimalarial, antiparasitic agents.
For example oleanolic acid are (Triterpene derivatives) agents with confirmed antiviral properties, also
effective against SARS-CoV-2. Triterpene compounds, as the basic skeleton, equipped with additional
elements of known antiviral (and similar) drugs are currently undergoing intensive studies to determine
their suitability for repurposing in COVID-19 therapy.
Till today favipiravir, remdesivir, galidesivir and tilorone as an antiviral drugs have been proposed for
introduction into the oleanolic acid structure in C-3 position of the triterpene backbone by the
hydroxyimino-, acetate- or dimethylsuccinate group as the linker.
Alkylamine substituent (derived from the chloroquine molecule or its analogs) have been proposed also
for attachment via an amide bond at the C-28 position of the triterpene backbone.
A combination of the above-mentioned three elements results in 18 designed complex structures with
significant antiviral properties which offering the greatest prospects for use in COVID-19 therapy.
Based on the selected methods of computational chemistry the molecular parameters and the preliminary
activity characterizing designed molecules as potential drugs were calculated and predicted.
The results of the above analysis show that among the designed complex structures with potential
antiviral activity targeting mainly SARS-CoV-2, the highest therapeutic potential is noted for the
compounds containing a molecule of favipiravir in addition to the N-alkylaminoalkylamide fragment
connected with oleanolic acid.
Owing to the presence of fragments of three drug substances with significant antiviral properties
incorporated into one molecule, the molecule will be active in at least two different phases of the
coronavirus life cycle as a multitarged drugs [29].
1.5 Clinical trials of repositioning antiviral drugs for COVID-19
Quick transmission of corona virus could be catastrophic for the life; developing new anti-SARSCoV-2
drugs from scratch is impractical to face the pressing global challenge [30]. Drug developing for treatment
of SARSCoV-2 is an emerging strategy, because these drugs have known pharmacokinetic and
pharmacodynamic properties, side effects and drug regimens [31].
Some scientist suggest to use anti-SARS-CoV, anti-MERS-CoV agents were chosen as an antiviral drug
for COVID-19. Furthermore, some known antiviral drugs like nucleoside analogs and protease inhibitors
were chosen as a repositioning drug for COVID-19. Some drugs including favipiravir, remdesivir,
lopinavir/ritonavir, chloroquine, hydroxychloroquine, ribavirin, darunavir, arb.i.d.ol, were clinically tested
against COVID-19 infection which are present in Figure 5. And they are recommended in guidelines of
different countries (Table 1) also[32].
1.5.1 Favipiravir
Drug favipiravir was developed by Toyama Chemical (Division of Fujifilm, Tokyo, Japan). After oral
administration, favipiravir is converted into the biologically active nucleoside triphosphate form. It was
approved for marketing in Japan in March 2014; generally is used as an antiviral treatment for influenza A
and B. Many studies have shown that favipiravir has a specific inhibitory effect on SARS-CoV2 (half
maximal effective concentration [EC50] = 61.88 μM, 50% Cytotoxic concentration [CC50] >400 μM, and
selectivity index [SI] >6.46) [33]. Avipiravir is recommended for use in further research in vivo.
After controlled study (ChiCTR2000029600) enrolled 80 patients, with 35 in the favipiravir group and
45 in the control group [34]. The results showed that the median time for the negative conversion of viral
nucleic acids in the favipiravir group was significantly shorter than it was in the participants in the control
group (4 vs 11 days; p < 0.001). In terms of chest imaging, the rate of improvement was also significantly
higher in the favipiravir group than that in the control group (91.43 vs 62.22%; p = 0.004).
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1.5.2 Remdesivir
The drug remdesivir is a prodrug developed by Gilead Science, whose structure resembles adenosine.
Holshue et al. 2020 [35] reported that the first patient with SARS-CoV-2 was treated with intravenous
remdesivir, which improved the clinical symptoms, including a decrease in body temperature, no need for
oxygen inhalation support and the return of oxygen saturation to 94–96%.
Gilead Sciences Inc., 2020 published the first clinical result from use of remdesivir [36]. In total from 53
patients with COVID-19, it is shown in 36 patients (68%) showed clinical improvement, and 25 patients
(47%) were discharged; eight patients (15%) showed worsening and seven patients (13%) died. In 32
patients (60%) it is shown side effects; 12 patients experienced serious side effects.
On 1 May 2020, Gilead Sciences Inc., announced that the US FDA had granted emergency use
authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19, and on 8 May 2020,
Japan approved remdesivir for use of treatment of patients with COVID-19 [37].
1.5.3 Lopinavir/ritonavir
Third drug lopinavir/ritonavir is recommended as a second-line treatment of HIV. Lopinavir/ritonavir
has been proved to be effective in SARS and MERS in vitro and in vivo [63].
Recent evidence suggests that lopinavir has antiviral activity in treatment of SARS-CoV-2 in vitro with
an IC50 value of 9.12 μM [64].
Lopinavir/ritonavir was not associated with benefit in hospitalized patients with COVID-19. The
difference in mortality between patients treated with lopinavir/ritonavir and the control group failed to
reach the statistically significant (19.2 vs 25.0%; difference: -5.8 percentage points; 95% CI, -17.3 to 5.7)
[65].
1.5.4 Chloroquine
Chloroquine phosphate has been recommended as an antimalarial drug for more than 70 years. The in
vitro anti-SARS-CoV-2 activity of chloroquine phosphate has been identified with an IC50 value of 1.13
μM; in this amount it is shown to be effective in preventing replication of this virus [76]. Gao et.al. 2020
[66] report that chloroquine phosphate was helpful in preventing the progression of COVID-19. In total,
120 patients with SARS-CoV-2 pneumonia were treated with chloroquine phosphate and 110 patients had
undetectable viral RNA on the throat swab after the treatment, and 81 patients were discharged. Also it is
not shown serious adverse reactions during the treatment with chloroquine. Based on these results,
chloroquine phosphate was included in China’s ’Diagnosis and Treatment Protocol for COVID-19 (trial
version 7)’ followed by inclusion into the protocols of several other countries.
1.5.5 Hydroxychloroquine
Hydroxychloroquine had earned a reputation for potential promising role in COVID-19 [38]. Recently,
chloroquine and hydroxychloroquine were demonstrated to inhibit SARS-CoV-2 in vitro (EC50 =
5.47%μM, EC50 = 0.72%μM, respectively) [39, 67].
The underlying mechanisms were inferred as follows: (1) as weakly alkaline, chloroquine could increase
endosomal pH therefore block virus infection [33, 38]; (2) as spike (S) protein angiotensin-converting
enzyme 2 (ACE2) blocker. It is shown that chloroquine and hydroxychloroquine interfered with the
glycosylation of cellular SARS-CoV receptor thus inhibit virus attacking [40]; (3) as immunomodulant,
chloroquine and hydroxychloroquine could counteract pro-inflammatory cytokine storm in critically ill
patients with COVID-19 [42, 48].
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Unfortunately, the outcomes of hydroxychloroquine in COVID-19 patients were inconsistent in SARSCoV-2 viral eradication. Gautret et al [39] reported that hydroxychloroquine alone or combined with
azithromycin observed better ability of SARS-CoV-2 eradication. At day six post-treatment, 100% of
patients treated with combination of hydroxychloroquine and azithromycin had been virologically cured
compared to 57.1% in patients treated with hydroxychloroquine alone and 12.5% in control group.
1.5.6 Ribavirin
The most extensively used therapies were ribavirin and ribavirinbased combinations. Ribavirin was
reported to tightly bind to SARSCoV- 2 ribonucleic acid (RNA) dependent RNA Polymerase (RdRp) with
binding energy of -7.8 kcal/mol, and thus may be used to against COVID-19 [50]. There were 9 studies
reporting SARS and MERS patients treated with ribavirin or combinations with ribavirin. The metaanalysis yielded inconsistent results for mortality with RR of between 0.38 and 0.82, while the combination
of ribavirin and corticosteroids showed remarkable lower mortality compared with control group.
1.5.7 Tocilizumab
Another drug which is use for patient’s treatments with SARS COVI-19 is Tocilizumab. A retrospective,
observational study (n = 21) administered 400 mg tocilizumab, an interleukin (IL)-6 blocker, intravenously
once to patients who had respiratory failure, shock or organ failure [57]. Although three patients received a
subsequent dose, the benefit is unknown (COVID-19 Investigation Team, 2020). However, the potential
benefit in decreasing mortality was evident as no deaths were reported out of 21 patients [53].
1.5.8 Ciclesonide
Ciclesonide is another drug which is used for patients with SARS COVID-19. An inhaled corticosteroid for
the treatment of asthma, which has been a potential candidate for repurposing in the treatment of patients
with MERS or COVID-19 [61]. The dosage used in a current trial was 320 mcg q12h for 14 days [58, 60,
62]. Ironically, systemic corticosteroids are contraindicated in severe pneumonia caused by viruses such as
MERS-CoV and SARS-CoV because they suppress the innate immune system, resulting in increased viral
replication.
1.5.9 Niclosamide
Another medication undergoing repurposing investigations for SARS-CoV-2 is niclosamide, an oral
anthelmintic drug used worldwide at a single dose of 2 g/d. Niclosamide exerts anti-MERS activity, inhibits
SARS-CoV replication and abolishes viral antigen synthesis in vitro, [27, 51] and is considered a possible
treatment option. However, it is cytotoxic and has low absorption including low oral bioavailability (10%)
and although efforts have been made to formulate derivatives to overcome these obstacles, its extensive
clinical development as an antiviral agent may still be hindered. An interventional trial has been registered
to evaluate the use of chloroquine with or without azithromycin, faviprevir, nitazoxanide or ivermectin for
the treatment of patients with COVID-19 in a real-life setting, but recruitment has not commenced as of 14
April 2020 [62].
1.5.10 High-dose intravenous immunoglobulin (IVIG)
The co-administration of high-dose intravenous immunoglobulin (IVIG) at 25 g/d for 5 days (body weight,
66 kg) with moxifloxacin was reported in a case series study [65]. Although no trials are currently
recruiting, the IVIG doses used in protocols are in the range of 0.2-0.5 g kg−1 day−1 and the use of this
agent is expected to be limited to patients in severe or critical conditions [62].
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Multidrug combinations

2.

The combination of multiple drugs is an important strategy for cure SARS-CoV-2 (Table 2). It is
common to combine drugs which interfere at different steps of the virus replication cycle to improve
antiviral efficacy and reduce of drug resistance. For example, the combination of endocytosis inhibitors and
protein kinase inhibitors blocks viral invasion. Cohen et al. 2020 [69], suggest combination of remdesivir
and dendritic protein monoclonal antibodies as an ideal treatment for SARS-CoV-2 infection. Many
clinical treatment of patients with SARS-CoV-2 have been carried out, including those with an RDRP
inhibitor, such as favipiravir in tablet form, combined with endocytosis inhibitor chloroquine phosphate, in
the treatment of COVID-19 (ChiCTR2000030987).
The combination of ribavirin with different types of interferon to enhance the innate antiviral response
was the most commonly used in the treatment of patients with a coronavirus infection (such as SARS and
MERS) [70, 71, 72].
Another combination is suggested to use such as interferon-β and antiviral drugs, (lopinavir/ritonavir),
has also been recommended by clinical experts [73].

3.

COVID -19 and Symptoms in different organs

3.1 COVID-19 & digestive symptoms
Further studies have identified the potential transmission of SARS-CoV-2 through blood and feces
samples of COVID-19 patients. The SARS-CoV-2 RNA has been detected in anal or rectal swabs and
blood of hospitalized COVID-9 patients [74, 78, 81]. In the study by Zhang et al 15 [78] patients tested,
eight were oral swabs positive (53.3%), four were anal swabs positive (26.7%), and six blood positive
(40%) and three serum positive (20%). Notably, anal swabs were found more test positive than oral swabs;
suggesting the transmission of fecal–oral of SARS-CoV-2. Further, in study by Xu et al., 2020 [75] in a
clinical investigation of ten pediatric COVID-19 confirmed cases, rectal swabs of eight children (80%)
were persistently tested RNA positive even after nasopharyngeal test was negative, presenting the evidence
of viral shedding through the GI tract.
3.2 Coronaviral hepatic pathogenesis
SARS-CoV-2 has been linked to mild-to-moderate liver injury; revealed by elevated serum
aminotransferases (ALT/AST), bilirubin, hypoproteinemia and prothrombin time prolongation, supported
by liver histopathology [77, 79, 81, 99, 101]. SARS-CoV-2 might directly affect intrahepatic bile ducts this
is shown by single-cell RNA sequencing data from two distinct cohorts of COVID-19 patients when it is
shown elevated expression of Angiotensin Converting Enzyme-2 receptor in cholangiocytes (59.7%) than
hepatocytes (2.6%) [80]. In a recent clinical study of 194 COVID-19 patients, 30 patients (15.46%) showed
liver dysfunction [81].
Chronic liver disease patients with impaired immunity because of classical hepatitis viruses (HBV,
HCV, HDV and HEV) or other hepatotropic viruses (HGV, GBV, TTV and SENV) infection or
nonalcoholic fatty liver disease/nonalcoholic steatohepatitis are more susceptible to COVID-19 [82].
SARS-CoV-2 is also proposed to cause viral hepatitis while inducing a dysregulated innate immune
response [83].
In the study by Wen et al., 2020 [84] it is shown the level of CD4+ and CD8+T were decreased
significantly, inflammatory genes were highly expressed in these patients. The B plasma cells were found
to be increased compared with decrease in the naïve B cells. Furthermore, IL-1β and macrophage-colony
stimulating factor (M-CSF) were predicted as novel candidate target genes for inflammatory storm whereas
TNFSF13, IL-18, IL-2 and IL-4 seemed to be beneficial for the recovery of COVID-19 patients.
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3.3 Transmission of SARS-CoV-2 by asymptomatic persons is implicated in crowd & familyclustered outbreaks
Multiple studies have found that there are asymptomatic SARS-CoV-2 infections in the process of
crowds and family-clustered outbreaks. Among a family of six in Shenzhen who traveled to Wuhan from
29 December 2019 to 4 January 2020, five members were identified with COVID-19, including an
asymptomatic 10-year-old boy [85]. A family members who traveled on 22 January 2020 from Wuhan to
Guangzhou, China, through the high-speed rail tested positive for SARS-CoV-2, but only one developed
clinical symptoms, and the other two members had no signs or clinical symptoms [86]. Asymptomatic
COVID-19 patients can even become the source of infection in contagious outbreaks among families.
SARS-CoV-2 transmission from an asymptomatic infected person returning home from Wuhan on 10
January 2020 was suspected as the cause of a family cluster epidemic of five members in Anyang, China
[87].
3.4 Lung
ACE2 is shown to be localized to the lungs, as has one of the angiotensin receptors, AT1, but not AT2.
There is a clear, the interaction of ACE2 and AT1 on lung protection in models of disease, including those
caused by coronaviruses [88, 89, 90]. Genetic knock-out of AT1a receptor expression markedly improved
lung function in mice with a genetic knockout of this receptor (Agtr1a-/- mice), confirming the function of
Ang-II in lung health [91, 92].
ACE2 knockout mice developed more severe ALI in models that result in respiratory distress (Nagase et
al., 2000). But injection of ACE2 show to protect mice with ALI [88].
Many researcher has demonstrated that the injection of SARS virus leads to an increase level of Ang-II
in lung tissue and exacerbates ALI in mice. It is shown the viral spike from SARS inhibit ACE2 and may
result in increases levels of Ang-II. The ACE gene that has been studied in details, the presence (insertion,
I) or absence (deletion, D) of a 287 base pair sequence of alu within intron 16 of the gene that encodes
ACE. The D genotype of ACE is associated with ARDS susceptibility and outcome, where DD genotype
was associated with ARDS [93, 94], although this has not been demonstrated in all populations [95].
The same genotype of ACE it is shown too associated with higher ACE activity, which, result in lower
Ang-II levels. More recent data on COVID-19 has demonstrated important differences in race on infection
rates and severity [96, 97, 98].
3.5 Heart
The study in coronaviruses has demonstrated that a high percentage of patients have cardiac dysfunction,
including cardiomyopathy and cardiac injury. In some publication it is shown a greater number of patients
who are hospitalized with COVID-19 and demonstrating cardiac injury [99]. This cardiac dysfunction
following the viral infection, is a temporary drop in ACE2 levels, due to ACE2 destruction as a result of the
infection. Previously data indicates that the infection can result in ACE2 destruction, reduction in
membrane-bound ACE2 and that ACE2 has a protective role in the heart [100, 101]. The disruption of
ACE2 accelerates cardiac hypertrophy and shortens the transition period to heart failure in an Ang-II model
of heart failure [102].
Patients who become infected with COVID-19 lose some of the pulmonary and cardiac protective
mechanisms of ACE2 and Ang(1–7), due to viral binding and the resultant destruction of ACE2 following
infection [101].
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Discussion and conclusion

4.

Here in this review we describe coronavirus disease 19 caused several acute respiratory syndrome. The
SARS CoVID-19 infection emerged in December 2019. This virus belongs betacoronavirus genera and
contain positive non-segmented RNA. The genome of CoVID-19 range between 27-32kDa; and have
spherical and pleomorphic form. Replication cycle is divide into three phase: a) viral entry; b) RNA
replication; c)exit from host cell.
Developing of new drug for patient treatment with CoVID-19 is impractical to face the pressing global
challenge. Many clinical and research laboratory suggest to used drugs such as Favipiravir, Remedesivir,
Lopinavir/ritonavir, Chloroquine, Hydroxychloroquine, Ribavirin, Tocilizumab, Ciclesonide, Niclosamide,
High-dose intravenous immunoglobulin (IVIG) and Multidrug combinations.
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Fig 1. Various proteins associated with SARS-CoV-2

Fig 2. Replication cycle of SARS-CoV-2. DMV: Double membrane vesicle; ER: Endoplasmic
reticulum; RTC: Replicase–transcriptase complex
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Fig 3. Potential drug targets and the corresponding inhibitors against SARS-CoV-2. E: Envelope; M:
Membrane; N: Nucleocapsid; S: Spike.
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Fig 4. Advancement of research on selected drugs used against various types of viruses, and possibilities
for their repurposing for SARS-CoV-2 therapy. The presented data are subject to current changes related to
the introduction of individual drugs into experimental therapies (Pawełczyk and Zaprutko 2020).

Fig 5. Structures and in vitro activities of repositioning antiviral drugs in clinic for SARS-CoV-2. CC50:
50% Cytotoxic concentration; EC50: Half maximal effective concentration; IC50: Half maximal inhibitory
concentration; SI: Selectivity index
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Abstract. An analysis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes
collected from the patients worldwide has identified mutations in the virus that could aid in drug and
vaccine development. The researchers found that the virus’s genetic diversity in most countries is similar to
what it is globally, suggesting that it was introduced repeatedly by many infected people in each country
rather than by a “patient zero.” The genetic analysis found 198 mutations that have occurred more than
once. “Mutations in themselves are not a bad thing; it is nothing to suggest SARS-CoV-2 is mutating faster
or slower than expected. Several factors, including pharmacogenetics, it is possible to contribute to interindividual variability in drug response. However, till today little is known about the host genetics
interaction with infection and COVID-19 progression. To understand the role of the host gene, we review
the current literature, aggregate readily available genetic resources, and provide some updated analysis
relevant to COVID-19 and associated phenotypes.
Keywords: SARS-CoV-2, gene information, genetic variability, gene expression, gene polymorphism
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Introduction

Inter-individual variability in drug disposition is major cause for lack of efficacy or adverse reactions to
pharmacological treatment in up to 50% of all patients, posing big challenges for medical care and drug
development. Post-market safety events resulting in drug withdrawals, boxed warnings or safety
communications affect 32% of all novel therapeutics approved by FDA from 2001 to 2010, leading to
substantial economic losses for pharmaceutical industry [1].
Furthermore, epidemiological data from the US shows that adverse drug reactions (ADRs) cause 8.25%
and 19.2% increase of hospital stay length and death rate, respectively, and severe ADRs are estimated to
be the 4th-6th leading cause of death [2]. It is estimated that 20–30% of these negative effects can be
attributed to genetic variations and more than 200 pharmacogenomic biomarkers have by now been
incorporated into pharmacogenetics labels that can provide clinically actionable information regarding drug
choice or dosing.
The absorption, distribution, metabolism, elimination (ADME) of most drugs are complex and involve
multiple enzymes and transporter systems. As a consequence, it is likely that the effects of functional
alteration in one ADME protein on drug response phenotypes can be amplified or compensated if they
coincide with functional variation in another component involved in the disposition of the same drug [3].
Importantly, while such combinatorial pharmacogenetic effects are plausible, only few examples have
been presented to date, including additive effects of functional CYP2D6 duplications and UGT2B7*2
genotype for codeine toxicity in breastfed neonates [4] and the balance between active CYP2D6 and
CYP2C19 alleles for amitryptiline toxicity [5].
Transmission [6] of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs primarily
via respiratory droplets from face-to-face contact and, to a lesser degree, via contaminated surfaces.
Aerosol spread may occur, but the role of aerosol spread in humans remains unclear. An estimated 48%to
62%of transmission may occur via presymptomatic carriers.
Common symptoms [7] in hospitalized patients include fever (70%-90%), dry cough (60%-86%),
shortness of breath (53%- 80%), fatigue (38%), myalgias (15%-44%), nausea/vomiting or diarrhea (15%-
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39%), headache, weakness (25%), and rhinorrhea (7%). Anosmia or ageusia may be the sole presenting
symptom in approximately 3%of individuals with COVID-19.
Common laboratory abnormalities [8] among hospitalized patients include lymphopenia (83%), elevated
inflammatory markers (eg, erythrocyte sedimentation rate, C-reactive protein, ferritin, tumor necrosis
factor-α, IL-1, IL-6), and abnormal coagulation parameters (e.g, prolonged prothrombin time,
thrombocytopenia, elevated D-dimer [46%of patients], low fibrinogen).
Common complications [7, 9, 10, 11, 12, 13] among hospitalized patients with COVID-19 include
pneumonia (75%); acute respiratory distress syndrome (15%); acute liver injury, characterized by
elevations in aspartate transaminase, alanine transaminase, and bilirubin (19%); cardiac injury, including
troponin elevation (7%-17%), acute heart failure, dysrhythmias, andmyocarditis; prothrombotic
coagulopathy resulting in venous and arterial thromboembolic events (10%-25%); acute kidney injury
(9%); neurologic manifestations, including impaired consciousness (8%) and acute cerebrovascular disease
(3%); and shock (6%).
1.1 Drug and gene information
162 drugs with pharmacogenetic labels were obtained from FDA [14], CPIC [15] and DPWG [16]. This
list was complemented with 100 top selling drugs, resulting in a total of 212 drugs for analysis. ADME
fingerprints of all compounds were extracted from DrugBank.
1.2 Pharmacogenetic data
Genetic variability data was obtained from Ingelman-Sundberg et al., 2018[17]. The minor allele
frequencies (MAFs) of variations classified as functional were aggregated and complemented with the
functional variants CYP1A2*1C (rs2069514), CYP1A2*1F (rs762551), CYP2C19*17 (rs12248560),
CYP3A4*22 (rs35599367), CYP3A5*3 (rs776746), CYP2B6*22 (rs34223104), CYP2C8*3 (rs10509681,
rs11572080), CYP2C9*3 (rs1057910), CYP2E1*2 (rs72559710) and UGT1A1*28 (rs8175347), which
were not included in the analyses. Furthermore, rs11572078 in CYP2C8 and rs2297595 in DPYD were
removed as false-positive predictions.
Zhou and Volker 2020 [18] extracted ADME information from 212 drugs encompassing 94 associated
genes involved in drug disposition or toxicity. The selected drugs were distributed across therapeutic areas
with most compounds being used in psychiatry (n = 40), oncology (n = 35) and cardiology (n = 28; Fig. 1).
The genes that were implicated in the disposition of most drugs were CYP3A4 (n = 141 drugs), ABCB1 (n
= 94 drugs), CYP2D6 (n = 92 drugs) and CYP2C19 (n = 64 drugs).
In addition to gene family- or subfamily-wide interactions, Zhou, Volker 2020 [18] found highly
specific interactions between individual gene pairs. For instance, of 94 ABCB1 substrates in our data set,
81 were also substrates of CYP3A4 (Fig. 2A). Accordingly, drugs that were transported by ABCB1 were
19.7% more likely to be also CYP3A4 substrates than expected by chance. Similarly, implication of
CYP2D6 was a decent predictor of CYP1A2 and CYP3A4 metabolism with ΔP values of 0.14 and 0.13,
respectively (Fig. 2B). Notably however, DPCYP3A4, CYP2D6 substantially lower than ΔPCYP3A4,
ABCB1. Further notable associations were found for SLCO1B1 that shared substantial overlap with
ABCC2 (ΔP = 0.57) and ABCB1 (ΔP = 0.43; Fig. 2C).
Finally, TPMT overlapped with NUDT15 (ΔP = 0.74), ABCC5 (ΔP = 0.72) and SLC29A1 (ΔP = 0.72)
but not with CYPs (ΔP < 0), UGTs (ΔP < 0) or SULTs (ΔP < 0; Fig. 3D) [18].
1.3 Gene expression of ACE2 and TMPRSS2 variants
Asselta et al., 2020 [22] found no significant evidence for ACE2; it is not sure if ACE2 is associated with
disease severity/sex bias in the Italian population, TMPRSS2 levels and genetic variants proved to be
possible candidate disease modulators, contributing to the observed epidemiological data among Italian
patients.
Children account for less than 2% of identified cases of coronavirus disease 2019 (COVID-19) [20, 23].
It is hypothesized that the lower risk among children is due to differential expression of angiotensinconverting enzyme 2 (ACE2) [21], the receptor that severe acute respiratory syndrome coronavirus 2
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(SARSCoV- 2) uses for host entry. Dong et al., [21] investigated ACE2 gene expression in the nasal
epithelium of children and adults.
The results from this study show age-dependent expression of ACE2 in nasal epithelium, the first point
of contact for SARS-CoV-2 and the human body. Covariate-adjusted models showed that the positive
association between ACE2 gene expression and age was independent of sex and asthma. Lower ACE2
expression in children relative to adults may help explain why COVID-19 is less prevalent in children [21].
A limitation of this study is that the sample did not include individuals older than 60 years.
The analysis by Asselta et al., 2020 [22] suggests a role for TMPRSS2 variants and expression levels in
modulating COVID-19 severity, a hypothesis that fosters a rapid experimental validation on large cohorts
of patients with different clinical manifestations.
1.4 Functional of CYP2D6 by assessing primaquine 5-hydroxylation
Cytochrome P450 (CYP) 2D6 is involved in the metabolism of approximately 25% of clinically used
drugs, including antidepressants, β-blockers, anticancer drugs, opioid analgesics, and antimalarial drugs
[23].Multiplexed targeted genotyping and MLPA analysis of 427 African–American, Asian, Caucasian,
Hispanic and Ashkenazi Jewish individuals identified the frequencies of 16 variant CYP2D6 alleles and the
copy number of exons 1, 4, 6 and 3 downstream region. It is shown that CYP2D6 metabolized
Hydroxychloroquine [24].
1.5 Function and polymorphism of CYP3A4 and CYP3A5
Among the four cytochrome P450 (CYP) 3A genes, the most expressed in the liver are CYP3A4 and
CYP3A5. Till today are reported eighty single nucleotide polymorphysms (SNP) of CYP3A4/5 to the
Human P450 Allele Nomeclature Committee. CYP3A4 alleles with minimal function compared with wild
type include the CYP3A4*6 and CYP4*17. The alleles which have moderately decreased or altered activity
include: CYP3A4*2,*8,*11,*12,*13,*16, and *18. CYP3A5 alleles with minimal function include the
splice variants CYP3A5*3,*5,*6 and CYP3A5*10, as well as the null allele CYP3A5*7. Alleles with
moderately decreased catalytic activity include CYP3A5*8 and CYP3A5*9. This report reviews the current
progress in the functional characterization of CYP3A4 and CYP3A5 SNPs and provides genotyping tests
for possible defective variants. A combination of genotyping tests for defective CYP3A4/CYP3A5
haplotypes will be necessary to understand the variations in the metabolism and clinical toxicity of a wide
variety of clinical drugs, since these two CYP proteins have overlapping substrate specificities [25].
1.6 Toll like receptor 7 (TLR7)
van der Made [26] and colleagues 2020 describe 2 independent families with rare germline variants in an
innate immune-sensing gene, toll-like receptor 7 (TLR7), that lead to severe disease in males who inherit
the mutated gene on a single copy of their X chromosome. The study implicates TLR7 as a critical node in
recognizing SARS-CoV-2 and initiating an early immune response to clear the virus and prevent the
development of COVID-19.
The study by van der Made and colleagues 2020 implicates insufficient control of viral replication via
TLR7 and innate immune sensing as a driver of severe COVID-19 in young, previously healthy males from
2 independent families. In the first family, the index case was a male patient, age 32 years, with severe
COVID-19 requiring mechanical ventilation in the intensive care unit (ICU). His 29-year-old brother died
of COVID-19. Whole-exome sequencing was performed in the index case, leading to the discovery of a 4nucleotide hemizygous deletion likely leading to a predicted total loss of function of TLR7 by introducing a
premature termination codon (c.2129_2132del; p.[Gln710Argfs*18]).
The index case in the second family was a male patient, age 21 years, with severe COVID-19
complicated by pulmonary embolisms requiring mechanical ventilation in the ICU. His 23-year-old brother
had severe COVID-19 and required ICU care. Exome sequencing revealed a missense variant (c.2383G>T;
p.[Val795Phe]), which was predicted as deleterious in all in silico prediction tools.
In conclusion, the study by van der Made [26] and colleagues 2020 provides evidence that rare
mutations in TLR7 were associated with severe COVID-19 in young males from 2 independent families.
While rare mutations in TLR7 are unlikely to be a major driver of severe disease in most individuals
infected with SARS-CoV-2, the genetic study begins to unravel the molecular underpinnings of COVID19. As additional genetic loci are identified, such data could lead to improved diagnostics and therapeutics,
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including rational repurposing of existing anti-inflammatory therapies in either early infection or late stage
severe disease.
In the study by Caspar et al [27] a series of 4 young male patients with severe COVID-19, rare putative
loss-of-function variants of X-chromosomal TLR7 were identified that were associated with impaired type I
and II IFN responses. These preliminary findings provide insights into the pathogenesis of COVID-19.
1.7 UGT1A1 gene UDP (glucuronosyltransferase family 1 member A1)
The UGT1A1 gene belongs to a family of genes that provide instructions for making enzymes called UDPglucuronosyltransferases. These enzymes perform a chemical reaction called glucuronidation, in which a
compound called glucuronic acid is attached (conjugated) to one of a number of different substances.
The protein produced from the UGT1A1 gene, called the bilirubin uridine diphosphateglucuronosyl
transferase (bilirubin-UGT) enzyme; UGT1A1 is the only enzyme that glucuronidates bilirubin, a substance
produced when red blood cells are broken down. UGT1A1 converts the toxic form of bilirubin
(unconjugated bilirubin) to its nontoxic form (conjugated bilirubin).
Chinese research group Yao et al., 2020 [28] has made research by, biochemical indicators of liver,
blood clotting mechanism, routine blood test, UGT1A1 * 28 gene polymorphism and other data of 40 cases
with COVID-19 admitted to the isolation ward of Tangdu Hospital were retrospectively analyzed. They
came to conclusion that COVID-19 combined with liver function injury may be due to the slight elevation
of transaminase, mostly around the second week of the disease course. Severe patients have a higher
proportion of liver injury, and critical type is an independent risk factor for liver injury.
1.8 VDR gene vitamin D receptor
The VDR gene is responsible for making a protein called vitamin D receptor (VDR), which allows the body
to respond to vitamin D. This vitamin can be acquired from foods in the diet or made in the body with help
from sunlight exposure. Vitamin D is involved in maintaining the proper balance of several minerals in the
body, such as calcium and phosphate; both calcium and phosphate are essential for the normal formation of
bones and teeth. One of vitamin D's major roles is to control the absorption of calcium and phosphate from
the intestines into the bloodstream. Vitamin D is also involved in several processes unrelated to bone and
tooth formation.
The VDR protein attaches (binds) to the active form of vitamin D, known as calcitriol. This interaction
allows VDR to partner with another protein called retinoid X receptor (RXR).
Vitamin D is produced in the skin under the influence of UVB-light from the sun or obtained via the diet
by eating fatty fish, enriched dairy products or supplements. Vitamin D is known to support a healthy bone
and severe deficiency may lead to osteomalacia or the rickets, which still occur in poor areas of the world.
In addition, vitamin D support key functions in many organs, including the brain, muscle and the immune
systems [29]. In fact, the vitamin D receptor (VDR) is expressed in most cell types and may activate
somewhere between 200-500 genes, many related to the immune system [30].
Substantial evidence supports a link between vitamin D deficiency and COVID-19 severity but it is all
indirect. Community-based placebo-controlled trials of vitamin D supplementation may be difficult.
Further evidence could come from study of COVID-19 outcomes in large cohorts with information on
prescribing data for vitamin D supplementation or assay of serum unbound 25(OH) vitamin D levels.
Meanwhile vitamin D supplementation should be strongly advised for people likely to be deficient [31].
Finally, the field of vitamin D and Covid-19 is very active and several trials are under way. Thus, new
data will come, which may change these conclusions. However, in the meantime the conclusions above can
be followed and we have massive data to say that vitamin D at low doses (1000-2000 IU/day) are safe and
not harmful, which is in line with the historical proverb: primum non nocere (first, do no harm) – but
potentially we may prevent a number of ARIs and perhaps also Covid-19 [30].
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1.9 APOE e4 Gene
The ApoE e4 genotype is associated with both dementia and delirium [32], with the e4e4 (homozygous)
genotype associated with a 14-fold increase in risk of Alzheimer’s disease [33] compared to the common
e3e3 genotype, in populations with European ancestries. Kuo et al 2020 [32], therefore, aimed to test
associations between ApoE e4 alleles and COVID-19 severity, using the UKB data.
The ApoE e4e4 allele increases risks of severe COVID-19 infection, independent of preexisting
dementia, cardiovascular disease, and type-2 diabetes. ApoE e4 not only affects lipoprotein function (and
subsequent cardio-metabolic diseases) but also moderates macrophage pro-/anti-inflammatory phenotypes
[34]. The novel coronavirus SARS-CoV-2 causing COVID-19 uses the ACE2 receptor for cell entry. ACE2
is highly expressed in type II alveolar cells in the lungs, where ApoE is one of the highly co-expressed
genes [35]. Further investigation is needed to understand the biological mechanisms linking ApoE
genotypes to COVID-19 severity.
2.

Discussion

We present a review and analysis of COVID-19 host genetics and related phenotypes. At the beginning of
the current outbreak of COVID-19 in January 2020, the guidelines are adopted for treating patients infected
with SARS-CoV-2 were established based on the previous experience with the MERS outbreak, although
clinical outcomes still need to be evaluated [43, 44]. We hope that this paper will help clinicians
understand, prioritize and monitor the drugs being used until results of clinical trials are available.
3.
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Fig. 1. Overview of the genes and drug considered for analysis. Large column plot depicts the number of
drug associations per gene. In total n = 212 genes were considered. The inlet shows the distribution of
drugs across therapeutic areas.

Fig. 2. Examples of specific interactions between pharmacogenes. The difference (DP) between the
posterior probability that gene 2 is involved in the disposition of a drug under the condition that gene 1 is
involved compared to the unconditional probability for metabolism by gene 1, defined as ΔP =
P(gene2|gene1) _ P(gene2) is shown for gene1 as ABCB1 (A), CYP2D6 (B), SLCO1B1 (C) and TPMT (D)
and the respective most closely correlated genes. Venn diagrams show the overlap of the number of drugs
for the top hits for each respective gene.
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Abstract:The study was based on a questionnaire for self-adminstered laxatives. Part of this study were 76
pharmacists from Municipality of Tetovo. The questionnaire was developed in two different languages,
Albanian and Macedonian. The response format included multiple choice questions in which the participants
were asked to choose the most reasonable answer for them on the given list of options. 35% of patients have
taken laxatives with doctor's recommendation, 36% from pharmacists recommendation. Only 17% of patients
have taken laxatives without recommendations. 48% of healthcare professionals for constipation treatment
recommend use of synthetic laxatives and 51% of them recommend use of natural-based laxatives. The most
common pharmaceutical forms of laxatives that pharmacists recommend the most, majority of them, 29%
have given herbal tea laxatives and 21% syrup forms of laxatives. Other types of pharmaceutical forms are
less given to patients. Pharmacists also have rarely encountered the appearance of side effects in patients
during
the
use
of
natural
laxatives.
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Introduction
Constipation does not have a consensus definition, neither ideal disease markers. Therefore, history and
physical examination become the major determinant of thediagnosis. Although physicians and patients may
interpret it differently, a widely used definition of constipation by medical personnel is to define constipation
as less than three bowel movements per week or according to Rome III criteria. While patients often equate
constipation with stool consistency, feelings of incomplete emptying, straining, and urge for defecation
[1].The prevalence of constipation based on the Rome III criteria has been reported at varying levels around
the world, from 8.2% to 32.9% [2]. Constipation can be classified as primary (idiopathic or functional) or
secondary (iatrogenic or because of organic disease), the latter being more common in older people [3]. The
management of constipation comprises of non-pharmacological, pharmacological and complementary
therapy to achieve and maintain regular bowel movements free of symptoms. The non-pharmacological
therapy includes life style modification as physical activity and bowel training, diet modifications by
increasing fluid and fiber intake. The pharmacological therapy includes laxatives such as bulk forming
laxatives, stool softeners, osmotic and saline laxatives, stimulant laxatives, and lubricants, as well as the
prokinetics agents. Complementary therapy includes olive oil, flaxseed oil, tincture of jalapa, and the
probiotics [4].

Aim
Based on the dynamic lifestyle of people nowadays, the number of patients suffering from constipation is
increasing day by day. Therefore this fact increased our interest to see how much is it consumed in pharmacies
and how much the pharmacists recommended the use of natural-based laxatives to treat constipation.

Material and methods
The study was based on a self-adminstered questionnaire where, part of this study were 76 pharmacists from
Municipality of Tetovo. Data were collected from March 3rd, 2020 to March 7th, 2020.The questionnaire
was developed in two different languages, Albanian and Macedonian. The response format included multiple
choice questions in which the participants were asked to choose the most reasonable answer for them on the
given list of options. The frequency of answers and results of the data derived from the research were
calculated by Microsoft Excel, version 2019.
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Results
Regarding to the question if the patients who come to the pharmacy take laxatives on their own or they ask
for a recommendation from pharmacists, we have achieved these answers: 35% of patients have taken them
with doctor's recommendation, 36% of patients have taken laxatives with pharmacist’s recommendation.Only
17% of patients have taken laxatives without recommendations. In the question where pharmacists were
asked for the type of the laxatives prescribed by doctor or recommended by them mostly of them wehave
achieved these results: 48% of healthcare professionals recommend use of synthetic laxatives and 51% of
them recommend use of natural-based laxatives for constipation treatment. Percentage of answers on the
question where pharmacists were asked for the most common pharmaceutical forms of laxatives that they
recommend the most, majority of them, 29%, have given herbal tea laxatives and 21% have given syrup
pharmaceutical forms of laxatives. Other types of pharmaceutical forms are less given to patients.
Pharmacists were also asked about which one of the natural laxatives including here: semen Psylli, semen
Lini, Lactulose, Folium Sennae, Cortex Frangulae, Rhamni purshiana, Rheum sp, Aloe or any other natural
laxative is the most consumed in their pharmacy, by patients. According to the data we obtained, most of the
patients, 14%, use Folium Sennae, followed by 12% of patients which use semen Lini more. 11% of patients
consider Lactulose as the most effective of the natural laxatives and for the 7% of them, Aloe is more
benefitial for constipation. Only 4% of patients use semen Psylli as laxative. Other laxatives that patients use
but, are not included in the answers are Figs, with 3% of total percentage. In the question: ’’Have your
patients ever reported side effects from the use of natural laxatives? ’’, of the 76 pharmacists surveyed,
majority, 52 of them, answered: ’’No, patients have not experienced side effects while using natural
laxatives’’. 14 of the pharmacists indicated that side effects have been reported in some specific patients and
only 10 of them answered:’’ Yes, patients have experienced side effects during use of natural laxatives’’.

Conclusion
According to the data derived from this research work we noticed that majority of pharmacists and doctors
recommend use of natural laxatives and they think that they are the best choice for constipation treatment.
Pharmacists also have rarely encountered the appearance of side effects in patients during the use of natural
laxatives.
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Abstract. Origanum vulgare and Hyssopus officinalis are important aromatic and medicinal plants. The
chemical composition of the volatile aroma compounds was defined in the fresh aerial part of Origanum
vulgare (f-O) and Hyssopus officinalis (f-H), collected in Valbona (Albania). The analysis were made by
gas chromatography – mass spectrometry (GC/FID/MS) on HP5-ms column and equipped with automated
headspace (HS) system. 0,3 g fresh plant material (homogenized samples from flower, leaf and stem) was
put in sealed vials, heated (80 ͦ C) and the gas phase was investigated. Total of 21 individual volatile aroma
compounds were identified in f-O sample, 14 monoterpenes (78.35%) and 7 sesquiterpenes (3.03%).
Dominant components were monoterpene hydrocarbons: sabinene (55.05%), trans-β-ocimene (5.19%) and
γ-terpinene (4.05%), followed by cis-sabinene hydrate, α-terpinene and β-pinene. In f-H sample were
identified 16 individual volatile aroma components, 11 monoterpenes (84.51%) and 5 sesquiterpenes
(0.29%). The major components were monoterpene hydrocarbons: β-pinene (48.66%) and cispinocamphone (29.77%), followed by α-pinene and α-thujene.
Keywords: Origanum vulgare, Hyssopus officinalis, aroma compounds, Headspace GC/FID/MS.

Introduction
Oregano (Origanum vulgare L.) is an important aromatic plant widely produced in many countries for
flavoring food. Oregano leaves and its essential oil were used in the food, drink, perfume, and cosmetics
industry due to its pleasant and highly desirable aroma. Historically, the composition of oregano leaves has
been studied using leaves oils obtained from hydrodistillates of the leaves. This approach produced samples
with high volatile concentrations which were necessary for extraction and identification technologies
available at that time. However, the heat applied during this process and long extraction time produced oils
whose smell bore only limited resemblance to the original leaves [1]. Numerous studies have shown that
Origanum vulgare subs.vulgare is poor in sources of volatiles and rich in acyclic compounds and
sesquiterpenoids. Its principal constituents are Sabinene, (Z)-β-Ocimene, β-Caryophyllene and Germacrene
D, while the phenols Thymol and Carvacrol are nearly absent. The essential oils of O. vulgare subsp.
vulgare have a high antimicrobial activity against bacteria, fungi and yeast [2]. In recent years, many of its
therapeutic properties have been demonstrated: antioxidant, antimicrobial, antiinflammatory, antiviral,
antispasmodic, antiproliferative, and neuroprotective, among others [3].
Hyssop (Hyssopus officinalis, synonym Hyssopus decumbens) is a herbaceous plant of the genus Hyssopus
native to Southern Europe, the Middle East, and the region surrounding the Caspian Sea [4]. A literature
review on the chemical and biological aspects of the plant indicates that the main constituents of H.
officinalis include several polyphenolic compounds, primarily the flavonoids apigenin, quercetin, diosmin,
luteolin and their glucosides followed by other phenolic compounds chlorogenic, protocatechuic, ferulic,
syringic, p-hydroxybenzoic and caffeic acids. Reports on the essential oils extracted from aerial parts of H.
officinalis revealed several principal components, including terpenoids pinocamphone, isopinocamphone
and β-pinene. Hyssop has moderate antioxidant and antimicrobial activity against Gram positive and
negative bacteria activities together with antifungal and insecticidal antiviral properties in vitro. Animal
model studies indicate myorelaxant, antiplatelet and α-glucosidase inhibitory activities for this plant [5].
The specific and particular aroma is maybe the most important reason for the wide use of the fresh and
dried aerial parts of Origanum vulgare and Hyssopus officinalis. Chemical composition of O.vulgare and
H. officinalis extracts as well as essential oil has been studied, but still very little is known about its aroma
components. There are not data about the volatile aroma compounds in the fresh aerial parts. To analyze
these compounds a refined method of headspace sampling hyphenated with GC/FID/MS analysis can be
utilized [6].
The aim of this work was the determination of the volatile aroma compounds in the fresh aerial parts of
Orignanum vulgare and Hyssopus officinalis using a headspace (HS) method with gas chromatography –
mass spectrometry (GC/FID/MS).
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Material and method
Plant material: The fresh aerial parts of Origanum vulgare (f-O) and Hyssopus officinalis (f-H) were
collected in Valbona (Albania).
Analyses of aroma compounds:
GC and GC-MS analyses: 0.3 g of fresh aerial parts (homogenized samples from flower, leaf and stem) of
f-O and f-H was put in sealed vials, warmed for 5 minutes and the gas phase (highly volatile compounds)
was investigated on Agilent 7890А Gas Chromatography system equipped with flame ionization detector
(FID) and Agilent 5975C Mass Quadrupole detector as well as capillary flow technology which enable
simultaneous analysis of the sample on both detectors. HP-5ms (30 m x 0.25 mm, film thickness 0.25 μm)
capillary column was used. Operating conditions were as follows: oven temperature 60°C, 20°C/min to
280°C; helium as carrier gas at a flow rate of 1 mL/min; injector temperature 260°C and FID temperature
270°C. 1000 μL of gas phase was injected at split ratio 1:1. The mass spectrometry conditions were:
ionization voltage 70 eV, ion source temperature 230°C, transfer line temperature 280°C and mass range
from 50-500 Da. The MS was operated in scan mode.
Headspace method: Incubation temperature 80˚C; incubation time 5 min; syringe temperature 85˚C;
agitator speed 500 rpm.
Identification of components: Identification of the components was made by comparing the mass
spectra of components with those from NIST, Wiley and Adams mass libraries, by AMDIS (Automated
Mass Spectral Deconvolution and Identification System) and by comparing literature and estimated
Kovat’s (retention) indices that were determined using a mixture of a homologous series of normal alkanes
from С9 to С25 in n-hexane, under the same conditions. The percentage ratio of the components was
computed by the normalization method of the GС/FID peak areas and average values were taken.

Results and discussion
Table 1 shows the relative percentage of the volatile components identified in the fresh aerial parts of O.
vulgare and H. officinalis; compounds are listed according to their linear retention indices.
Table 1. Chemical composition of volatile aroma compounds in the fresh aerial parts of Origanum
vulgare (f-O) and Hyssopus officinalis (f-H) (%)
Fresh
Origanum
vulgare (f-O) (%)

Fresh Hyssopus
officinalis (f-H)
(%)

N.

Components

KIL

1.

α-Thujene

931

2.25

1.14

2.

α-Pinene

939

1.90

3.12

3.

Camphene

953

0.20

0.51

4.

Sabinene

976

55.05

-

5.

β-Pinene

980

2.38

48.66

6.

α-Phellandrene

1005

0.37

-

7.

α-Terpinene

1018

2.40

-

8.

β-Phellandrene

1031

-

0.11
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9.

trans-β-Ocimene

1040

5.19

0.69

10.

γ-Terpinene

1062

4.05

0.06

11.

cis-Sabinene hydrate

1068

2.96

-

12.

Terpinolene

1088

0.56

0.10

13.

cis-Thujone

1102

-

0.17

14.

allo-Ocimene

1129

-

0.17

15.

Isoborneol

1156

0.12

-

16.

cis-Pinocamphone

1173

-

29.77

17.

α-Terpineol

1189

0.80

-

18.

Thymol, methyl ether

1235

0.15

-

19.

α-Copaene

1376

-

0.01

20.

β-bourbonene

1384

0.14

-

21.

α-Gurjunene

1409

-

0.01

22.

trans- Caryophyllene

1418

1.01

-

23.

α-Guaiene

1439

-

0.02

24.

α-Humulene

1454

0.14

-

25.

trans-9-epiCaryophyllene

1467

0.14

-

26.

Germacrene D

1480

1.28

0.10

27.

Bicyclogermacrene

1494

0.25

0.15

28.

γ-Cadinene

1513

0.06

-

81.41

84.80

Total (%):

KIL- Kovats (retention) index- literature data [7]; (-) did not identify.

Total of 21 individual volatile aroma compounds were identified in fresh aerial parts of Origanum
vulgare (f-O), representing 81.41 % of the total content (Table 1). Data analysis of the chemical
composition revealed three different classes of components: monoterpene hydrocarbons (MH) (9
compounds) 73.79%, oxygen containing monoterpenes (OM) (5 compounds) 4.59% and sesquiterpene
hydrocarbons (SH) (7 compounds) 3.03%. The abundant components (> 1%) in f-O sample were MH:
sabinene (55.05%), trans-β-ocimene (5.19%), γ-terpinene (4.05%), α-terpinene (2.40%), β-pinene (2.38%)
and α-thujene (2.25%), followed by OM: cis-sabinene hydrate (2.96%) as and SH: germacrene D and transcaryophyllene.
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In fresh aerial parts of Hyssopus officinalis (f-H) were identified total of 16 individual volatile
aroma compounds, representing 84.80% of the total content (Table 1). Data analysis of the chemical
composition revealed three different classes of components: monoterpene hydrocarbons (MH) (8
compounds) 54.46%, oxygen containing monoterpenes (OM) (3 compounds) 30.04% and sesquiterpene
hydrocarbons (SH) (5 compounds) 0.29%. The major components (> 1%) were monoterpene hydrocarbons:
β-pinene (48.66%), α-pinene (3.12%) and α-thujene (1.14%), as and OM cis-pinocamphone (29.77%).
Hatipi et al. analyzed the chemical composition of the essential oil of wild Origanum vulgare collected
from different locations in Kosovo using GC/MS method. Main identified individual compounds were
sabinene (1.81-12.34 %), 1,8-cineole (1.31-13.54 %), caryophyllene oxide (0.18-38.05 %),(E)-βcaryophyllene (0.48-14.0%), p-cymene (1.27-19.62 %), α-terpineol (1.05-19.23 %), and germacrene D
(0.35-16.09 %) [8]. Compared with these data, in the HS GC-FID/MS profile of our sample of fresh aerial
part of O. vulgare, sabinene was dominant component (55.5%) as and germacrene D exceeded 1%
(1.28 %).
Moghtader reported iso pinocamphone (38.47%), pinocomphone (13.32%), n-decane (8.67%),
pinocarvone (5.34%) and β-pinene (1.54 %) as dominant components of the essential oil of the fresh leaves
as and iso pinocamphone (40.25%), pinocomphone (14.92%), n-decane (8.63%), pinocarvone (6.76%) and
β-pinene (1.78 %) as dominant components of the essential oil of the fresh flowers of Hyssopus officinalis,
collected in Iran, analysed by GC and GC/MS [4]. In our tested sample of fresh aerial part of H. officinalis,
only cis-pinocamphone (29.77 %) and β-pinene (48.66 %) were the dominant compounds. The other
compounds were not identified in our tested sample.

Conclusion
Responsible compounds of the specific and particular aroma of the fresh aerial part of O. vulgare and H.
officinalis, collected in Valbona (Albania) and analyzed by the HS-GC / FID / MS method belong to the
group of mono and sesquiterpenes. The dominant individual compounds in both analyzed samples were
monoterpenes: sabinene in the f-O sample as and β-pinene and cis-pinocamphone in the f-H sample.
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